http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210024081-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate | 2019-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20210024081-A |
| titleOfInvention | How to use GIP/GLP1 coagonists for diabetes |
| abstract | Type 2 diabetes (T2D) using a novel dosing regimen of a GIP:GLP-1 peptide having a GIP:GLP-1 receptor agonist potency ratio of about 2.5:1 to about 10:1 GIP to GLP-1 Provides a way to cure. Moreover, the present invention provides a method of treating T2D using a novel dosing regimen of a GIP:GLP-1 peptide having a GIP:GLP-1 receptor agonist potency ratio of about 2.5:1 to about 5:1 GIP to GLP-1. Provides. In addition, the present invention provides a method of inducing T2D remission using a novel dosing regimen of GIP:GLP-1 peptide. The present invention also provides a method of treating obesity using a novel dosing regimen of GIP:GLP-1 peptide. |
| priorityDate | 2018-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 118.